Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +110.71% and +10.22%, respectively, for the quarter ended March 2026. Do the…
51,540$
-1,42%
Echtzeit-Aktienkurs Supernus Pharmaceuticals
Bid:
Ask:
Nachrichten zur Supernus Pharmaceuticals Aktie
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline
Supernus (SUPN) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on…
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript
…
Pivotal-Point Nachverfolgung Supernus Pharmaceuticals (SUPN): Kursziel-Explosion nach Piper Sandler-Upgrade – Parkinson-Medikament Onapgo als neuer Umsatz-Star!
Supernus Pharmaceuticals ist ein auf die Biopharmazie spezialisiertes Unternehmen, das sich auf die Entwicklung und Vermarktung von Produkten zur Behandlung…
Pivotal-Point Nachverfolgung Supernus Pharmaceuticals (SUPN): Kursziel-Explosion nach Piper Sandler-Upgrade – Parkinson-Medikament Onapgo als neuer Umsatz-Star!
Supernus Pharmaceuticals ist ein biopharmazeutisches Unternehmen aus den USA, das sich auf die Entwicklung und Kommerzialisierung von Produkten zur Behandlung…
Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Lets find out.…
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +93.62% and +7.34%, respectively, for the quarter ended June 2025. Do the…
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript
…
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and…
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.…
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage…
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Investors need to pay close attention to Supernus Pharmaceuticals (SUPN) stock based on the movements in the options market lately…
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 10.53% and 2.91%, respectively, for the quarter ended March 2025. Do the…
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on…
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript
…
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the…
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on…
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript
…
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 171.79% and 13.30%, respectively, for the quarter ended September 2024. Do the…
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster,…
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on…
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
Supernus (SUPN) delivered earnings and revenue surprises of -2.70% and 13.12%, respectively, for the quarter ended June 2024. Do the…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript
…
Supernus Announces First Quarter 2024 Financial Results
ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on…
Supernus Pharmaceuticals exec sells over $500k in stock By Investing.com
Supernus Pharmaceuticals exec sells over $500k in stock…
Supernus Pharmaceuticals exec sells $436k in stock By Investing.com
Supernus Pharmaceuticals exec sells $436k in stock…
Supernus Pharmaceuticals executive sells over $2.1m in stock By Investing.com
Supernus Pharmaceuticals executive sells over $2.1m in stock…
Supernus Pharmaceuticals executive trades company stock By Investing.com
Supernus Pharmaceuticals executive trades company stock…
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
…